{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T03:01:55Z","timestamp":1780282915480,"version":"3.54.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archivos de la Sociedad Espa\u00f1ola de Oftalmolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.oftale.2026.502465","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T07:53:22Z","timestamp":1773042802000},"page":"502465","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of intravitreal Ziv-Aflibercept for the treatment of macular edema: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8035-4874","authenticated-orcid":false,"given":"F.","family":"Munayco-Guill\u00e9n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1970-799X","authenticated-orcid":false,"given":"M.","family":"Garc\u00eda-Roa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2447-3334","authenticated-orcid":false,"given":"M.","family":"V\u00e1zquez-Membrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3316-4557","authenticated-orcid":false,"given":"R.","family":"Pichardo-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.oftale.2026.502465_bib0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4103\/0974-9233.172293","article-title":"Updates on the clinical trials in diabetic macular edema","volume":"23","author":"Demirel","year":"2016","journal-title":"Middle East Afr J Ophthalmol"},{"issue":"5","key":"10.1016\/j.oftale.2026.502465_bib0010","doi-asserted-by":"crossref","first-page":"e540","DOI":"10.1111\/aos.14328","article-title":"Ziv-aflibercept: a cost-effective, off-label, highly potent antagonist of vascular endothelial growth factor","volume":"98","author":"Mansour","year":"2020","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.oftale.2026.502465_bib0015","first-page":"561","article-title":"Intravitreal ziv-aflibercept: clinical effects and economic impact","volume":"6","author":"Singh","year":"2017","journal-title":"Asia-Pacific J Ophthalmol"},{"key":"10.1016\/j.oftale.2026.502465_bib0020","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1080\/08820538.2019.1641526","article-title":"Intravitreal Ziv-Aflibercept: a comprehensive review","volume":"6","author":"Barmas-Alamdari","year":"2019","journal-title":"Semin Ophthalmol"},{"issue":"2","key":"10.1016\/j.oftale.2026.502465_bib0025","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/ICB.0000000000000449","article-title":"Intravitreal injections of Ziv-Aflibercept for the treatment of a patient with macular edema secondary to branch retinal vein occlusion","volume":"12","author":"Andrade","year":"2018","journal-title":"Retin Cases Brief Rep"},{"issue":"3","key":"10.1016\/j.oftale.2026.502465_bib0030","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/1120672119833267","article-title":"Correlation analysis of fundus autofluorescence, spectral domain optical coherence tomography, and visual function in patients with diabetic macular oedema treated with intravitreal ziv-aflibercept","volume":"29","author":"Hernandez-Da Mota","year":"2019","journal-title":"Eur J Ophthalmol"},{"issue":"6","key":"10.1016\/j.oftale.2026.502465_bib0035","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1097\/IAE.0000000000000913","article-title":"Short-term safety profile of intravitreal Ziv-Aflibercept","volume":"36","author":"Chhablani","year":"2016","journal-title":"Retina"},{"issue":"10","key":"10.1016\/j.oftale.2026.502465_bib0040","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1097\/IAE.0000000000001440","article-title":"Short-term safety of 2 mg intravitreal Ziv-Aflibercept","volume":"37","author":"Chhablani","year":"2017","journal-title":"Retina"},{"issue":"4","key":"10.1016\/j.oftale.2026.502465_bib0045","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3928\/23258160-20180329-06","article-title":"Intravitreal ziv-aflibercept for diabetic macular edema: 48-week outcomes","volume":"49","author":"De Andrade","year":"2018","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"2","key":"10.1016\/j.oftale.2026.502465_bib0050","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1136\/bjophthalmol-2016-308679","article-title":"Three-month outcome of intravitreal ziv-aflibercept in eyes with diabetic macular oedema","volume":"101","author":"Mansour","year":"2017","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"10.1016\/j.oftale.2026.502465_bib0055","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1136\/bjophthalmol-2018-312453","article-title":"Safety of 5914 intravitreal ziv-aflibercept injections","volume":"103","author":"Singh","year":"2019","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"10.1016\/j.oftale.2026.502465_bib0060","article-title":"Three-month outcome of ziv-aflibercept for diabetic macular edema","volume":"4","author":"Marashi","year":"2016","journal-title":"Adv Ophthalmol Vis Syst"},{"issue":"5","key":"10.1016\/j.oftale.2026.502465_bib0065","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.oret.2017.09.010","article-title":"One-year results of a trial comparing 2 doses of intravitreal ziv-aflibercept versus bevacizumab for treatment of diabetic macular edema","volume":"2","author":"Jabbarpoor Bonyadi","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oftale.2026.502465_bib0070","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.2147\/OPTH.S116343","article-title":"Intravitreal ziv-aflibercept for macular edema following retinal vein occlusion","volume":"10","author":"Paulose","year":"2016","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.oftale.2026.502465_bib0075","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.2147\/OPTH.S428792","article-title":"Intravitreal ziv-aflibercept versus bevacizumab for na\u00efve central retinal vein occlusion with macular edema: an interim analysis of a randomized non-inferiority trial","volume":"17","author":"Sinawat","year":"2023","journal-title":"Clin Ophthalmol"},{"issue":"2","key":"10.1016\/j.oftale.2026.502465_bib0080","doi-asserted-by":"crossref","first-page":"164","DOI":"10.18502\/jovr.v18i2.13182","article-title":"Ziv-aflibercept in diabetic macular edema: relation of subfoveal choroidal thickness with visual and anatomical outcomes","volume":"18","author":"Moradian","year":"2023","journal-title":"J Ophthalmic Vis Res"},{"key":"10.1016\/j.oftale.2026.502465_bib0085","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.2147\/OPTH.S398359","article-title":"Effectiveness of the use of three-dose intravitreal ziv-aflibercept in the management of diabetic macular edema in a real-life setting","volume":"17","author":"Munayco-Guill\u00e9n","year":"2023","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.oftale.2026.502465_bib0090","first-page":"40","article-title":"Use of ziv-aflibercept in diabetic macular edema in a Ghanaian population","volume":"36","author":"Braimah","year":"2022","journal-title":"Eye (Basingstoke)"},{"issue":"7","key":"10.1016\/j.oftale.2026.502465_bib0095","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.4103\/ijo.IJO_1532_18","article-title":"Bevacizumab versus ziv-aflibercept in branch retinal vein occlusion","volume":"67","author":"Braimah","year":"2019","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.oftale.2026.502465_bib0100","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ajoc.2017.10.011","article-title":"One-year outcomes of ziv-aflibercept for macular edema in central retinal vein occlusion","volume":"8","author":"Eldeeb","year":"2017","journal-title":"Am J Ophthalmol Case Rep"},{"issue":"7","key":"10.1016\/j.oftale.2026.502465_bib0105","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1007\/s10792-021-01799-w","article-title":"Efficacy of intravitreal ziv-aflibercept in patients with macular edema following retinal vein occlusion in Korle-Bu Teaching Hospital, Ghana: a retrospective case series","volume":"41","author":"Braimah","year":"2021","journal-title":"Int Ophthalmol"},{"issue":"3","key":"10.1016\/j.oftale.2026.502465_bib0110","article-title":"Short-term safety of 2 mg of intravitreal ziv-aflibercept in different retinal pathologies","volume":"93","author":"Meza-Anguiano","year":"2019","journal-title":"Rev Mex Oftalmol (Engl Ed)"},{"key":"10.1016\/j.oftale.2026.502465_bib0115","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.oret.2016.08.007","article-title":"Two doses of intravitreal Ziv-Aflibercept versus bevacizumab in treatment of diabetic macular edema: a three-armed, double-blind randomized trial","volume":"1","author":"Baghi","year":"2017","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.oftale.2026.502465_bib0120","doi-asserted-by":"crossref","first-page":"e803","DOI":"10.1111\/aos.13352","article-title":"Comparison between the short\u2010term outcomes of bevacizumab and ziv\u2010aflibercept in the treatment of primary diabetic macular oedema","volume":"95","author":"Ashraf","year":"2017","journal-title":"Acta Ophthalmol"},{"issue":"7","key":"10.1016\/j.oftale.2026.502465_bib0125","doi-asserted-by":"crossref","first-page":"e669","DOI":"10.1111\/aos.13111","article-title":"Three\u2010month outcomes of ziv\u2010aflibercept in the treatment of diabetic macular oedema","volume":"94","author":"Ashraf","year":"2016","journal-title":"Acta Ophthalmol"},{"issue":"8","key":"10.1016\/j.oftale.2026.502465_bib0130","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1136\/bjophthalmol-2014-306319","article-title":"Ziv-aflibercept in macular disease","volume":"99","author":"Mansour","year":"2015","journal-title":"Br J Ophthalmol"},{"issue":"5","key":"10.1016\/j.oftale.2026.502465_bib0135","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3928\/23258160-20170428-06","article-title":"Safety and efficacy of Ziv-Aflibercept in the treatment of refractory diabetic macular edema","volume":"48","author":"Ashraf","year":"2017","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.oftale.2026.502465_bib0140","doi-asserted-by":"crossref","first-page":"685","DOI":"10.2147\/OPTH.S199411","article-title":"Role of peripheral pan-retinal photocoagulation in diabetic macular edema treated with intravitreal ziv-aflibercept","volume":"13","author":"Mansour","year":"2019","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"10.1016\/j.oftale.2026.502465_bib0145","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1080\/08820538.2019.1686528","article-title":"Intravitreal Ziv-Aflibercept: safety analysis in eyes receiving more than ten intravitreal injections","volume":"35","author":"Singh","year":"2020","journal-title":"Semin Ophthalmol [Internet]"},{"issue":"7","key":"10.1016\/j.oftale.2026.502465_bib0150","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1136\/bjophthalmol-2018-312593","article-title":"Long-term outcome of treat and extend intravitreal ziv-aflibercept therapy","volume":"103","author":"Mansour","year":"2019","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"10.1016\/j.oftale.2026.502465_bib0155","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1136\/bjophthalmol-2016-309724","article-title":"Long-term safety and efficacy of ziv-aflibercept in retinal diseases","volume":"101","author":"Mansour","year":"2017","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"10.1016\/j.oftale.2026.502465_bib0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0223944","article-title":"Safety of intravitreal ziv-aflibercept in choroido-retinal vascular diseases: a randomised double-blind intervention study","volume":"14","author":"Braimah","year":"2019","journal-title":"PLoS One"}],"container-title":["Archivos de la Sociedad Espa\u00f1ola de Oftalmolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173579426000563?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173579426000563?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T02:42:52Z","timestamp":1780281772000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173579426000563"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2173579426000563"],"URL":"https:\/\/doi.org\/10.1016\/j.oftale.2026.502465","relation":{},"ISSN":["2173-5794"],"issn-type":[{"value":"2173-5794","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of intravitreal Ziv-Aflibercept for the treatment of macular edema: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Archivos de la Sociedad Espa\u00f1ola de Oftalmolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oftale.2026.502465","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.oftal.2026.502465","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Sociedad Espa\u00f1ola de Oftalmolog\u00eda. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"502465"}}